Publication

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

Authored by:

Kim, S., Lee, G. and Goldie, S.

Full Citation

Kim, S., Lee, G. and Goldie, S. 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infectious Diseases. 10(260).

View Publication

Additional key concepts from this publication:

Vaccines are among the most cost-effective health interventions available.

Key Evidence: Assuming 90% coverage, a 9-valent PCV (PCV9) program in The Gambia would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs, for the birth cohort over the first 5 years of life. The estimated cost would be $670 per DALY averted in The Gambia.

Herd effects multiply the benefits of immunization.

Key Evidence: Assuming 90% coverage, a program in The Gambia using a 9-valent PCV (PCV9) would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs over the first 5 years of life of a birth cohort. The estimated cost would be $670 per DALY averted in The Gambia.